Company: SXTPW
Filing Date: 2025-07-16
Form Type: 424B4
Source: 0001213900-25-064472
Chunk: 46

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-16
Form: 424B4
Chunk 46
---
 stock and decrease or eliminate your investment.

Our common stock is listed on The Nasdaq Capital
Market. If we violate the maintenance requirements for continued listing of our common stock, our common stock may be delisted. In the
past, we have received letters from Nasdaq notifying us that we were not in compliance with the $1.00 minimum bid price requirement for
continued listing on Nasdaq under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Although we have complied with the
Bid Price Rule as of the date of this prospectus, there can be no assurance that we will maintain compliance with the Bid Price Rule or
any other applicable Listing Rules of Nasdaq. Nasdaq could issue us another letter notifying us of our non-compliance if our shares of
common stock trade less than $1.00 per share for 30 consecutive business days, and in that event, subsequently make a determination to
delist our common stock if we fail to take appropriate action.

Nasdaq requires us to have, among other requirements,
including the Bid Price Rule, a minimum amount of shareholders’ equity of $2.5 million in order to maintain our listing. Currently,
our as adjusted shareholders’ equity is $4,028,889 as of March 31, 2025. A delisting of our common stock from Nasdaq may materially
impair our stockholders’ ability to buy and sell our common stock and could have an adverse effect on the market price of, and the
efficiency of the trading market for, our common stock. In addition, the delisting of our common stock could significantly impair our
ability to raise capital. Also, our Board may determine that the cost of maintaining our listing on a national securities exchange outweighs
the benefits of such listing. An active trading market for our shares may never develop or be sustained.

<div align='center'>23</div>

Any delisting determination by Nasdaq could seriously
decrease or eliminate the value of an investment in our common stock and other securities linked to our common stock. While a listing
on an over-the-counter exchange could maintain some degree of a market in our common stock, we could face substantial material adverse
consequences, including, but not limited to, the following: limited availability for market quotations for our common stock; reduced liquidity
with respect to and decreased trading prices of our common stock; a determination that shares of our common stock are “penny stock”
under the SEC rules, subjecting